Candel Therapeutics Inc Cash Flow-to-Debt Ratio
Candel Therapeutics Inc cash flow-to-debt ratio. Candel Therapeutics Inc (CADL) has a Cash Flow-to-Debt Ratio of -0.28x as of March 2026, meaning its operating cash flow of $-18.04 Million could theoretically repay 0% of its total liabilities ($63.89 Million) in one year. Check how high is Candel Therapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Candel Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of Candel Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for Candel Therapeutics Inc across 7 annual periods. Also explore how fast is Candel Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Candel Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Candel Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Candel Therapeutics Inc. For the full cash flow conversion analysis, see Candel Therapeutics Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.52x | $-38.31 Million | $73.27 Million | ▲ +21.6% |
| 2024 | -0.67x | $-27.02 Million | $40.54 Million | ▲ +44.6% |
| 2023 | -1.20x | $-34.24 Million | $28.46 Million | ▼ -18.0% |
| 2022 | -1.02x | $-31.42 Million | $30.80 Million | ▼ -15.1% |
| 2021 | -0.89x | $-22.22 Million | $25.07 Million | ▼ -504.3% |
| 2020 | -0.15x | $-9.07 Million | $61.84 Million | ▼ -52.8% |
| 2019 | -0.10x | $-5.18 Million | $53.94 Million | — |